Professor Harry Iland AM
MBBS (Hons) FRACP FRCPA MHGSA
Professor Iland is a Clinical Professor at the University of Sydney and a Senior Staff Specialist at Royal Prince Alfred Hospital.
His major clinical and laboratory passion has been the investigation and management of acute promyelocytic leukaemia (APL), and he has been responsible for the Australasian Leukaemia and Lymphoma Group (ALLG) clinical trial program in APL since 1997.
The APML4 regimen, which has been a major achievement of that program, has received international recognition, and has proven to be practice-changing in the US, Canada and Australia.
Professor Iland’s contributions to APL research have been acknowledged internationally by invitations to (1) speak at clinical plenary sessions of the 6th (2013), 7th (2017) and 8 th (2024) International APL Symposium in Rome, (2) write a chapter on front-line therapy for the definitive textbook on APL, and (3) join the European LeukemiaNet committee that publishes guidelines for the investigation and management of APL.
He established one of the earliest diagnostic molecular haematopathology laboratories focusing on haematological malignancies in Australia, and his laboratory has identified and published novel molecular variants of acute promyelocytic leukaemia (the PRKAR1A-RARA fusion), core binding factor AML (the type J CBFB-MYH11 fusion), and a novel XK gene mutation in the McLeod syndrome. Currently, he chairs the Measurable Residual Disease Reference Committee for the ALLG AMLM26 INTERCEPT study.